[ad_1]
Johnson End Johnson (USA Johnson End Johnson)Early safety studies revealed that J & J’s novel coronavirus infection candidate (COVID19) vaccine resulted in a long-lasting immune response with a single inoculation.
13According to the publications, more than 90% of the subjects produced neutralizing antibodies within 29 days after vaccination and 100% within 57 days. The immune response lasted 71 days until the end of the study period.
J&J Chief Scientific Officer Paul Stoffels said in an interview yesterday that “there are good expectations and reasons for efficacy when testing antibodies” in a late-stage trial with upcoming results. ..
The company’s vaccine, which requires only one inoculation, produces more neutralizing antibodies than the single-shot vaccine developed by other innovators. However, the immune response of competing products is comparable to that of J & J’s single-dose vaccine at the end of the two doses, Stoffels explained.
Preliminary results from a phase 1/2 study involving 805 people over the age of 18 were published in the American medical journal New England Journal of Medicine (NEJM) on day 13. These data have been added to the more limited results. posted by J&J last September.
The company hopes to see how the vaccine worked in a late-stage study involving 45,000 people in a few weeks. Stoffels noted that the effectiveness could be even greater than 70%, based on the first results and more.
Infectious disease experts are paying close attention to the progress of J & J’s vaccines, as single-dose vaccines will be much easier to inoculate in large doses.
J & J’s stock price temporarily rose 1.3% in overtime trading on the 13th.
Will the J&J corona vaccine get permission in the US in March?
Original title:
J&J Single Shot Vaccine Provides Long-Lasting Response in Early Study (1) （抜 粋）
